Related Experiment Video
Updated: Jun 22, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil
D Cosco1, D Paolino, R Muzzalupo
1Department of Pharmacobiological Sciences, Faculty of Pharmacy, University "Magna Graecia" of Catanzaro, Campus Universitario "Salvatore Venuta", Building of BioSciences, Viale Europa, 88100 Germaneto, CZ, Italy.
Abstract:
Innovative niosomes made up of α,ω-hexadecyl-bis-(1-aza-18-crown-6) (bola), Span 80® and cholesterol (2:5:2 molar ratio) are proposed as suitable delivery systems for the administration of 5-fluorouracil (5-FU), an antitumoral compound largely used in the treatment of breast cancer. The bola-niosomes, after sonication procedure, showed mean sizes of ~200 nm and a loading capacity of ~40% with respect to the amount of 5-FU added during the preparation. Similar findings were achieved with PEG-coated bola-niosomes (bola, Span 80(R), cholesterol, DSPE-mPEG2000, 2:5:2:0.1 molar ratio respectively). 5-FU-loaded PEG-coated and uncoated bola-niosomes were tested on MCF-7 and T47D cells. Both bola-niosome formulations provided an increase in the cytotoxic effect with respect to the free drug. Confocal laser scanning microscopy studies were carried out to evaluate both the extent and the time-dependent bola-niosome-cell interaction. In vivo experiments on MCF-7 xenograft tumor SCID mice models showed a more effective antitumoral activity of the PEGylated niosomal 5-FU at a concentration ten times lower (8 mg/kg) than that of the free solution of the drug (80 mg/kg) after a treatment of 30 days.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
COP Coated Vesicles
Drug Delivery Systems: Different Types
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Modified-Release Drug Delivery Systems: Site-Targeted
Drugs for Treatment of Ulcerative Colitis in IBD

